LABORATORY
DEALS
Why Laboratory Transactions Need Specialists
Diagnostics deals are not generic M&A. Reimbursement regimes, accreditation
(e.g., ISO 15189), quality systems, LDT/IVD mix, equipment age, and referral
concentration all shape both valuation and risk.
Laboratory Deal Process
Step-by-Step Guidance
From Readiness to Closing
• Readiness review: compliance, CAP/ISO, EHS, data privacy, device listings
• Financial & operational model: test volumes, CPT/EBM codes, margins by line
• Buyer mapping & outreach (under NDA), teaser + CIM tailored to lab buyers
• Diligence orchestration: quality, IT/LIS integration, instrument leases, vendor contracts
• Structure & price: cash vs. earn-out, R&W, retention and medical director agreements
• LOI through SPA: protect value, cap liabilities, align closing conditions with operations
Recurring referral base, scalable automation, LIS interoperability, sub-specialty moats, and payer stability push multiples up. Single-referrer dependency, undocumented LDTs, or weak QA depress value. We surface strengths and pre-empt issues before diligence.
Typical levers we highlight: turnaround times, quality KPIs, device lifecycle, reagent pricing, capacity headroom, and pipeline of institutional contracts.
Sector-Native Storytelling
We translate your metrics into buyer language that commands premium valuations.
Diligence Without Disruption
We run a clean, time-boxed process so clinical operations keep running smoothly.
Risk-Aware Structuring
Earn-outs, R&W, and closing conditions designed for lab realities — not generic templates.
Closing Certainty
From NDA to SPA, we align legal, clinical, and commercial workstreams to hit dates and preserve value.
